Bukwang Pharm to commercialize hepatitis B drug clevudine in 2004

Bukwang Pharm said it would commercialize an innovative hepatitis B drug, clevudine (L-Fmau-102), nucleoside analogue, in 2004, as the phase IIb clinical trials in eight university hospital in Korea, demonstrated its excellent antiviral activity.

Clevudine has proven to manifest its sustained antiviral effects after discontinuation of medication and during the course of treatment and follow-...